|
|
|
|
| LEADER |
02847nmm a2200325 u 4500 |
| 001 |
EB001492268 |
| 003 |
EBX01000000000000000921857 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
170703 ||| eng |
| 020 |
|
|
|a 9783319582900
|
| 100 |
1 |
|
|a Whitcup, Scott M.
|e [editor]
|
| 245 |
0 |
0 |
|a Pharmacologic Therapy of Ocular Disease
|h Elektronische Ressource
|c edited by Scott M. Whitcup, Dimitri T. Azar
|
| 250 |
|
|
|a 1st ed. 2017
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2017, 2017
|
| 300 |
|
|
|a VIII, 394 p
|b online resource
|
| 505 |
0 |
|
|a General Principles: Principles of Ocular Pharmacology -- Ocular Pharmacokinetics -- Ocular Drug Delivery -- Anterior Segment and Tear Film: Tear Film-dry eye -- Conjunctiva-allergic conjunctivitis, infectious conjunctivitis, conjunctival hyperemia -- Cornea-Keratitis, antibiotics, antifungals, anti-virals, anti-inflammatory agents including corticosteroids and NSAIDS -- Cornea-Keratoconus and other corneal disease, Pharmacologic cross-linking and future therapy -- Lens-management of cataract surgery, cataract prevention, floppy iris syndrome -- Trabecular Meshwork and Uvea: Glaucoma-Intraocular Pressure Reduction -- Glaucoma-Neuroprotection -- Uveitis -- Posterior Segment and Optic Nerve: Retina Anti-angiogenesis, AMD, Myopia, DME -- Retina Anti-inflammatory therapy, corticosteroids, anti-complement, AMD, DME -- Atrophic AMD -- Hereditary Retinal Disease -- Optic Nerve
|
| 653 |
|
|
|a Pharmaceutical technology
|
| 653 |
|
|
|a Ophthalmology
|
| 653 |
|
|
|a Ophthalmology
|
| 653 |
|
|
|a Pharmaceutical Sciences/Technology
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Pharmacology/Toxicology
|
| 700 |
1 |
|
|a Azar, Dimitri T.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Handbook of Experimental Pharmacology
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-58290-0?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|
| 520 |
|
|
|a There have been major advancements in the pharmacologic treatment of eye diseases over the past decade. With newly discovered disease targets and novel approaches to deliver therapeutic compounds to the eye, patients are seeing improved outcomes. Not only are there better treatments for diseases where treatments existed, we now have effective therapy for previously untreatable and blinding eye disorders. This volume will cover the pharmacologic treatment of eye diseases from the front of the eye including eyelids, conjunctiva and cornea all the way back to the retina and optic nerve. The first section of the volume reviews general principles of ocular pharmacology, pharmacokinetics, pharmaceutical sciences, and drug delivery. In addition, the volume provides an up to date guide to the pharmacologic approach to the key eye diseases that threaten sight or ocular function
|